Scilex Holding Company Announces New Data From Deeper Skin Penetration Studies to Support SP-103 (lidocaine topical system) 5.4%, a Triple Strength Formulation of ZTlido®, in Treatment of Musculoskeletal Pain Disorders

PALO ALTO, Calif., Nov. 02, 2023 -- Scilex Holding Company , an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for...

Related Keywords

Florida ,United States ,Orlando ,California ,Palo Alto ,Canada ,Austria ,American ,Dmitri Lissin ,Multidisciplinary Digital Publishing Institute ,Scilex Or Company ,American Association Of Pharmaceutical Scientists ,Institute For Biomedical Research ,Drug Administration ,Scilex Holding Company Nasdaq ,Scilex Holding Company All Rights ,Scilex Holding Company ,Globenewswire Inc ,Pivotal Trialc Le Ar Program ,Semnur Pharmaceuticals Inc ,Scilex Pharmaceuticals Inc ,Exchange Commission ,Holding Company ,Biomedical Research ,Pharmaceutical Scientists ,Digital Publishing Institute ,Topical Delivery ,Post Herpetic Neuralgia ,Chief Medical Officer ,Lumbosacral Radicular Pain ,Private Securities Litigation Reform Act ,Pharmaceuticals Inc ,Holding Company All Rights ,Markets ,